Lenalidomide Krka (Lenalidomide)

Lenalidomide is used in hematologic malignancies and bone‑marrow failure disorders, targeting abnormal plasma cells and dysplastic clones.

• Multiple myeloma: reduces disease progression and improves survival in patients with relapsed or refractory disease.
• Myelodysplastic syndromes: decreases transfusion dependence and modifies disease course in patients with lower‑risk MDS.

• Lenalidomide binds to cereblon, a component of the CRL4‑E3 ubiquitin ligase complex, altering substrate specificity and promoting degradation of transcription factors such as Ikaros and Aiolos. This leads to modulation of cytokine production, inhibition of angiogenesis, and enhanced immune‑mediated tumor cell killing, while also exerting anti‑inflammatory effects.

Lenalidomide may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Fatigue: persistent tiredness affecting daily activities.
• Diarrhea: loose stools that may require fluid replacement.
• Rash: mild to moderate skin eruptions.
• Peripheral neuropathy: tingling or numbness in extremities.
• Nausea: upset stomach often alleviated with food.
• Constipation: reduced bowel movements.

Serious or Rare Side Effects

• Deep vein thrombosis or pulmonary embolism: blood clots requiring immediate medical attention.
• Severe neutropenia: markedly low white blood cell count increasing infection risk.
• Secondary primary malignancies: emergence of new cancers unrelated to the original disease.

When prescribing Lenalidomide, clinicians should consider several safety and handling measures.

• Monitor blood counts: perform regular complete blood count assessments to detect cytopenias.
• Assess renal function: adjust use in patients with impaired kidney function.
• Evaluate thromboembolic risk: consider prophylactic anticoagulation in high‑risk individuals.
• Counsel on teratogenic potential: enforce strict contraception for patients of child‑bearing potential.
• Store at ambient temperature: keep tablets in original container, protect from moisture and light.

Lenalidomide interacts with several drug classes, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid)

• Strong CYP3A4 inducers (e.g., rifampin): may lower plasma concentrations of lenalidomide.
• Anticoagulants (e.g., warfarin): increased risk of bleeding when combined.

Moderate Interactions (Monitor Closely)

• Immunosuppressants (e.g., cyclosporine): may enhance hematologic toxicity.
• Vaccines (live attenuated): reduced vaccine efficacy; avoid during treatment.
• NSAIDs (e.g., ibuprofen): may increase risk of renal impairment.